Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31 2022 - 3:31PM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, today announced that it
has granted inducement stock options to purchase an aggregate of
89,550 shares of its common stock to 12 new employees. The
inducement stock options have a grant date of August 31, 2022 and
were granted as inducements material to the new employees entering
into employment with Biocept in accordance with Nasdaq Listing Rule
5635(c)(4).
The inducement stock options have an exercise price of $1.03 per
share, the closing price of Biocept’s common stock on August 31,
2022, are non-qualified stock options, have a ten-year term and
vest over four years, with 25% of the shares vesting on the
one-year anniversary of the vesting commencement date and the
remaining 75% of the shares vesting in equal monthly installments
over the following 36 months, subject to the new employees’
continued service with Biocept through the applicable vesting
dates. The inducement stock options are subject to the terms and
conditions of Biocept’s Amended and Restated 2013 Equity Incentive
Plan, as amended.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes cerebrospinal fluid
tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220831005840/en/
Investor and Media Contact: Jody Cain, LHA Investor
Relations Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Apr 2024 to May 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From May 2023 to May 2024